To further explore the efficacy of Pon and the synergy between Tra and Pon in vitro, we extended the drug treatment to several human myeloma cell lines (HMCLs), including OPM2 with t(4;14) translocation, MM.1S with oncogenic KRAS mutation, H929 with t(4;14) translocation and oncogenic NRAS mutation, and Delta47 without either event21–23. This evidence concerns the gene NRAS and plasma cell myeloma.